Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L. salivarius CECT5713 for Reproductive Failure
NCT04446572Phase 2Completed
- Sponsor
- Complutense University of Madrid
- Start
- Oct 2018
- Primary completion
- Nov 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label trial of ligilactobacillus salivarius CECT5713 in recurrent miscarriage (RPL) and Unexplained infertility (3 arms), sponsored by Complutense University of Madrid. Primary endpoint: Pregnancies and successful pregnancies at 6 months. Started Oct 2018; status: completed.
02
Drugs
ligilactobacillus salivarius CECT5713
03
Conditions
recurrent miscarriage (RPL)Unexplained infertility
Beyond the preview
Go deeper on NCT04446572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446572.